OptimizeRx Strengthens Executive Leadership with Appointment of Chief Commercial Officer
2019年4月29日 - 9:31PM
OptimizeRx Corp. (NASDAQ: OPRX), a leading platform for digital
health messaging in the pharmaceutical industry, has appointed
Stephen Silvestro to the new position of chief commercial officer.
Silvestro will be responsible for driving OptimizeRx’s platform
revenue growth, including enterprise level direct-to-patient and
direct-to-provider product adoption to improve patient outcomes.
“We are thrilled to welcome Steve to the team, as he brings
important experience, depth of knowledge and a shared determination
to provide affordability and adherence solutions that link the
health care and life sciences industries,” said Will Febbo, CEO at
OptimizeRx. “During his tenure at Decision Resources Group, he was
an instrumental leader in the growth of the company from $30
million to $180 million in revenue. His customer-first philosophy
is greatly aligned to our values at OptimizeRx.
“We are confident in the market appetite for our solutions. We
believe Steve will drive incredible growth with our core clients
and take the company to the next level in terms of reach, revenue
and earnings.”
OptimizeRx is the largest point-of-care network in the U.S.,
reaching over half the ambulatory market. Through their digital
health platform, pharma companies have critical access to doctors
and their patients to provide medication information and savings.
The acquisition of CareSpeak and announcement of expansion into
health and hospital systems reflect technology capabilities to
deliver savings and adherence messages throughout the entire care
continuum.
Silvestro commented: “It’s an exciting time to join the
OptimizeRx team. We see a sustained growth opportunity for the
business driven by strong industry momentum to improve connections
between pharma, healthcare providers and patients. There is ample
room to grow with more than $1 billion of total addressable market.
This opportunity is amplified by the more than $528 billion
non-adherence impact which simply isn’t acceptable.
“I’m passionate about improving outcomes for patients, and
OptimizeRx provides a unique vehicle to help. I’m excited to help
lead the organization through its next phase of growth and to bring
some of the best practices and strong commercial discipline from my
years of building and leading best in class commercial
organizations.”
Silvestro previously served as vice president and general
manager at CCH Tagetik, a division of Wolters Kluwer. Prior pharma
leadership experience includes executive positions with Prognos,
Decision Resources Group and D.M.S. Silvestro has extensive channel
expertise in biopharma commercialization, global market access,
market research, analytics, enterprise SaaS solutions and
strategy.
Silvestro received a master’s degree in Business Management from
Harvard University. He also holds undergraduate degrees from
Brigham Young University in both Business and Italian. He is fluent
in English, Italian, Spanish and conversational in French. He will
be based in Boston, Massachusetts.
For more information on OptimizeRx, visit OptimizeRx.com.
About OptimizeRx
OptimizeRx® (NASDAQ: OPRX), a digital health company, connects
pharmaceutical companies to patients and providers, offering
greater affordability, adherence and brand awareness at the
point-of-care. As the nation’s largest point-of-prescribe
promotional platform for the pharmaceutical
industry, OptimizeRx provides a direct channel for pharma
companies to communicate with healthcare providers right within
their workflow and also directly to patients.
The cloud-based solution supports patient adherence to
medications and better healthcare outcomes with real-time access to
financial assistance, prior authorization, education and critical
clinical information. OptimizeRx provides more than half
of the ambulatory patient market with access to these benefits
through leading EHR platforms like Allscripts, Amazing Charts and
Quest, and directly via its mobile communications
platform.
For more information, follow the company
on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the definition of Section 27A of the Securities Act of 1933, as
amended, and such as in section 21E of the Securities Act of 1934,
as amended. These forward-looking statements should not be used to
make an investment decision. The words 'estimate,' 'possible' and
'seeking,' and similar expressions identify forward-looking
statements, which speak only as to the date the statement was made.
The company undertakes no obligation to publicly update or revise
any forward-looking statements, whether because of new information,
future events, or otherwise. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted, or quantified. Future events and actual results could
differ materially from those set forth in, contemplated by, or
underlying the forward-looking statements. The risks and
uncertainties to which forward-looking statements are subject
include, but are not limited to, the effect of government
regulation, competition and other material risks.
OptimizeRx ContactDoug Baker, CFOTel (248)
651-6568 x807dbaker@optimizerx.com
Media Relations ContactNicole Brooks, Innsena
Communications(Tel) 860-800-2344nicolebrooks@innsena.com
Investor Relations ContactRon Both, CMATel
(949) 432-7557oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 6 2024 まで 7 2024
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 7 2023 まで 7 2024